Nonrelapse deaths, relapse, response to DLI, and second transplantations according to diagnosis and disease status at RCBT
| Remission or phase/disease status at RCBT . | N . | Nonrelapse deaths, n . | Relapse, n . | Median time from RCBT to relapse, mo (range) . | DLI . | Second transplantations* . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N . | Response, n† . | Median duration of response, y (range)† . | N . | Response, n† . | Median duration of response, y (range)† . | |||||
| Acute leukemia | ||||||||||
| First CR/early | 31 | 3 | 10 | 8.0 (1.0-27.8) | 1 | 1 | 15.7 | 4 | 4 | 4.0 (1.1-8.7) |
| Second CR/int | 51 | 4 | 23 | 8.7 (1.5-17.5) | 4 | 1 | 1.8 | 7‡ | 2 | 5.4 (2.5-8.3) |
| Third or more CR/int | 13 | 4 | 5 | 4.6 (1.0-13.5) | 0 | NA | NA | 2 | 0 | NA |
| Refractory/advanced | 14 | 2 | 9 | 3.2 (0.4-7.9) | 1 | 0 | NA | 0 | NA | NA |
| MDS Advanced | 17 | 0 | 8 | 3.7 (0.6-26.0) | 1 | 0 | NA | 5‡ | 2 | 5.0 (3.0-6.9) |
| CML | ||||||||||
| First chronic phase/early | 9 | 0 | 6 | 11.9 (4.9-43.7) | 2 | 1 | 13.4 | 2 | 0 | NA |
| Accelerated phase/int | 3 | 0 | 2 | 28.5 (9.9-47.1) | 2 | 1 | 5.3 | 1‡ | 1 | 9.2 |
| Lymphoma, second or more CR/int | 3 | 0 | 0 | NA | 0 | NA | NA | 0 | NA | NA |
| Solid tumors, advanced | 6 | 0 | 4 | 7.5 (5.6-9.7) | 0 | NA | NA | 0 | NA | NA |
| Total | 147 | 13 | 67 | 6.8 (0.4-47.1) | 11 | 4 (36%) | 9.2 (1.8-15.7) | 21 | 9 (43%) | 6.0 (1.1-9.2) |
| Remission or phase/disease status at RCBT . | N . | Nonrelapse deaths, n . | Relapse, n . | Median time from RCBT to relapse, mo (range) . | DLI . | Second transplantations* . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N . | Response, n† . | Median duration of response, y (range)† . | N . | Response, n† . | Median duration of response, y (range)† . | |||||
| Acute leukemia | ||||||||||
| First CR/early | 31 | 3 | 10 | 8.0 (1.0-27.8) | 1 | 1 | 15.7 | 4 | 4 | 4.0 (1.1-8.7) |
| Second CR/int | 51 | 4 | 23 | 8.7 (1.5-17.5) | 4 | 1 | 1.8 | 7‡ | 2 | 5.4 (2.5-8.3) |
| Third or more CR/int | 13 | 4 | 5 | 4.6 (1.0-13.5) | 0 | NA | NA | 2 | 0 | NA |
| Refractory/advanced | 14 | 2 | 9 | 3.2 (0.4-7.9) | 1 | 0 | NA | 0 | NA | NA |
| MDS Advanced | 17 | 0 | 8 | 3.7 (0.6-26.0) | 1 | 0 | NA | 5‡ | 2 | 5.0 (3.0-6.9) |
| CML | ||||||||||
| First chronic phase/early | 9 | 0 | 6 | 11.9 (4.9-43.7) | 2 | 1 | 13.4 | 2 | 0 | NA |
| Accelerated phase/int | 3 | 0 | 2 | 28.5 (9.9-47.1) | 2 | 1 | 5.3 | 1‡ | 1 | 9.2 |
| Lymphoma, second or more CR/int | 3 | 0 | 0 | NA | 0 | NA | NA | 0 | NA | NA |
| Solid tumors, advanced | 6 | 0 | 4 | 7.5 (5.6-9.7) | 0 | NA | NA | 0 | NA | NA |
| Total | 147 | 13 | 67 | 6.8 (0.4-47.1) | 11 | 4 (36%) | 9.2 (1.8-15.7) | 21 | 9 (43%) | 6.0 (1.1-9.2) |
RCBT indicates related cord blood transplantation; DLI, donor lymphocyte infusion; CR, complete remission; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; int: intermediate.
Donor types: 15 with bone marrow (n = 14) or peripheral blood stem cells (n = 1) from the same donor; 1 haploidentical stem cell transplantation from the mother (acute myeloid leukemia in first CR), 3 unrelated bone marrow (1 acute lymphoblastic leukemia [ALL] in second CR, 1 MDS, 1 CML in accelerated phase), and 2 unspecified donor types (1 ALL in first CR, 1 ALL in third or more CR).
Response to DLI or second transplantation was defined as no relapse or death occurring after treatment until the date of last follow-up.
A total of 3 patients (one with acute leukemia, one with MDS, and one with CML) received a second transplantation after failure of DLI.